Bio/Pharma News

Oct 26, 2017
By Pharmaceutical Technology Editors
The collaboration aims to improve the pharmacokinetics of anti-C3 proteases developed by Catalyst to develop therapeutics for severe eye disorders.
Oct 26, 2017
By Pharmaceutical Technology Editors
Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.
Oct 26, 2017
By Pharmaceutical Technology Editors
The biotechnology company’s drug for treating hives in adults has been granted an expanded indication by the European Commission to treat children and adolescents.
Oct 25, 2017
By Pharmaceutical Technology Editors
Russian biotechnology company Biocad plans to enter the European market with oncological and autoimmune medicines.
Oct 23, 2017
By Pharmaceutical Technology Editors
The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.
Oct 20, 2017
By Pharmaceutical Technology Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 20, 2017
By Pharmaceutical Technology Editors
This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.
Oct 16, 2017
By Pharmaceutical Technology Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 16, 2017
By Pharmaceutical Technology Editors
Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.
Oct 16, 2017
By Pharmaceutical Technology Editors
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
native1_300x100
lorem ipsum